EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

RAAS blockade in the kidney life-cycle–treatment standard

Diego Moriconi iD, Clara Garcia-Carro, Julio Nuñez iD, Ricardo Correa-Rotter, Katherine Tuttle iD, María José Soler iD

Nephrology Dialysis Transplantation · 30.06.2026 · 41 (7) · 1227-1238

DOI: 10.1093/ndt/gfag090 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 20.04.2026. Verfasst von Diego Moriconi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Renin-Angiotensin System, Angiotensin-Converting Enzyme Inhibitors, Renal Insufficiency, Chronic, Angiotensin Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, CDC HHS, Travere.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The renin–angiotensin–aldosterone system (RAAS) plays a central role in regulating renal hemodynamics, sodium and water balance, and cardiovascular homeostasis. Chronic RAAS activation contributes to hypertension, proteinuria, inflammation, fluid overload, and fibrosis, making RAAS blockade (RAASb) a cornerstone therapy across the kidney life cycle. Over the past decades, ACE inhibitors, angiotensin receptor blockers, direct renin inhibitors, and mineralocorticoid receptor antagonists (MRAs) have demonstrated substantial benefits in slowing chronic kidney disease (CKD) progression, reducing proteinuria, and lowering cardiovascular risk. However, the efficacy and safety of RAASb vary according to the kidney life cycle. Evidence supports its use in proteinuric CKD and even in advanced stages, whereas the benefit in non-proteinuric disease remains limited. Novel non-steroidal MRAs such as finerenone further enhance renal and cardiovascular protection, particularly in persons with diabetes and CKD. In dialysis populations, RAASb may preserve residual kidney function and improve cardiac structure/function, although the benefit of steroidal MRAs remains uncertain. In kidney transplantation, RAASb appears safe and may improve long-term graft and patient survival, particularly when initiated early. The emergence of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists has reshaped therapeutic strategies, with accumulating evidence supporting complementary rather than competing roles with RAASb. This review synthesizes current evidence on RAAS modulation across the kidney life cycle from primary prevention to advanced CKD, dialysis, and transplantation, highlighting both established benefits and areas of current clinical uncertainty.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renin-Angiotensin SystemAngiotensin-Converting Enzyme InhibitorsRenal Insufficiency, ChronicAngiotensin Receptor AntagonistsMineralocorticoid Receptor AntagonistsHumansKidney Transplantation

Stichwörter der Autor:innen

RAAS blockadechronic kidney diseasedialysiskidney transplantation

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • AP-HP, Pharmacology Unit, Hopital Européen Georges Pompidou, Paris, France.
  • Nephrology Department, San Carlos University Clinical Hospital, Madrid, Spain.
  • Department of Cardiology, Hospital Clínico Universitario de Valencia, Fundación de Investigación INCLIVA, Valencia, Spain.
  • Department of Medicine, Universidad de Valencia, INCLIVA, CIBER Cardiovascular, Valencia, Spain.
  • Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

ORCID-Profile: Diego Moriconi, Julio Nuñez, Katherine Tuttle, María José Soler

Förderung

  • NIH HHS
  • CDC HHS
  • Travere
  • Bayer
  • Doris Duke Charitable Foundation
  • Benaroya Research Institute
  • Breakthrough T1D
  • Juvenile Diabetes Research Foundation

Zitieren

APA

Moriconi, D., Garcia-Carro, C., Nuñez, J., Correa-Rotter, R., Tuttle, K., & Soler, M. J. (2026). RAAS blockade in the kidney life-cycle–treatment standard. Nephrology Dialysis Transplantation, 41(7), 1227-1238. https://doi.org/10.1093/ndt/gfag090

Vancouver

Moriconi D, Garcia-Carro C, Nuñez J, Correa-Rotter R, Tuttle K, Soler MJ. RAAS blockade in the kidney life-cycle–treatment standard. Nephrology Dialysis Transplantation. 2026;41(7):1227-1238. doi:10.1093/ndt/gfag090

BibTeX
@article{Moriconi2026,
  author = {Moriconi, Diego and Garcia-Carro, Clara and Nuñez, Julio and Correa-Rotter, Ricardo and Tuttle, Katherine and Soler, María José},
  title = {RAAS blockade in the kidney life-cycle–treatment standard},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  volume = {41},
  number = {7},
  pages = {1227--1238},
  doi = {10.1093/ndt/gfag090}
}
Kostenlos starten →